May 27, 2009

CONTACT: Holly Auer
(215) 349-5659
holly.auer@uphs.upenn.edu


Penn Medicine Physician Named to Entertainment Industry’s Groundbreaking Anti-Cancer Campaign, “Stand Up to Cancer”

Abramson Cancer Center-Led “Dream Team” Will Tackle Pancreatic Cancer

PHILADELPHIA – Abramson Cancer Center Director Craig Thompson, MD, PhD, has been selected to lead a research “Dream Team” for Stand Up To Cancer, the groundbreaking partnership between the nation’s entertainment industry and the cancer research community. Armed with $18 million in funding, Thompson’s team is poised to lead the nation’s most innovative pancreatic cancer research project, which will discover more about what metabolic nutrients pancreatic tumors rely on to grow and develop new therapies designed to cut off that essential fuel. Despite the myriad advances in treating other cancers, people diagnosed with pancreatic cancer still face a grim prognosis – as many as 80 percent of patients who get the news die within a year.

To learn more about the project, see:

###

The Abramson Cancer Center (ACC) of the University of Pennsylvania is a national leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute for more than 30 years, one of 41 such Centers in the United States. The ACC is dedicated to innovative and compassionate cancer care. The clinical program, composed of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient support specialists, currently sees over 50,000 outpatient visits, 7400 inpatient discharges, and provides over 25,000 chemotherapy treatments, and more than 66,000 radiation treatments annually. Not only is the ACC dedicated to providing state-of-the-art cancer care, the latest forms of cancer prevention, diagnosis, and treatment are available to our patients through clinical themes that developed in the relentless pursuit to eliminate the pain and suffering from cancer. In addition, the ACC is home to the 300 research scientists who work relentlessly to determine the pathogenesis of cancer. Together, the faculty is committed to improving the prevention, diagnosis and treatment of cancer. More information is available at penncancer.org.

PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is currently ranked #3 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to the National Institutes of Health, received over $366 million in NIH grants (excluding contracts) in the 2008 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center, named one of the nation’s “100 Top Hospitals” for cardiovascular care by Thomson Reuters. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.


This release is available online at
http://www.uphs.upenn.edu/news/News_Releases/2009/05/stand-up-to-cancer-pancreatic-dream-team.html